Summary by Moomoo AI
Allarity Therapeutics, Inc. has filed an amended Schedule 13G/A with the Securities and Exchange Commission (SEC) on February 12, 2024, indicating a change in ownership by certain reporting persons. The filing was made by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, who now collectively own 653,377 shares of Allarity Therapeutics' common stock, representing 9.9% of the company. This ownership percentage is based on 5,886,934 outstanding shares as reported in the company's preliminary proxy statement filed on January 26, 2024. The shares include potential conversions and exercises of preferred stock, warrants, and a senior convertible note, all subject to beneficial ownership blockers that prevent ownership exceeding certain thresholds. The Reporting Persons have entered into a Joint Filing Agreement and have shared power to vote and dispose of the shares. The filing updates beneficial ownership information and amends previous disclosures, without indicating any intention to change or influence the control of Allarity Therapeutics.